Keywords: apoptosis caspase-9 sun ginseng synergistic effect a b s t r a c t Background: Sun ginseng (SG), a specific formulation of quality-controlled red ginseng, contains approximately equal amounts of three major ginsenosides (RK1, Rg3, and Rg5), which reportedly has antitumor-promoting activities in animal models. Methods: MTT assay was used to assess whether SG can potentiate the anticancer activity of epirubicin or paclitaxel in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells; apoptosis status was analyzed by annexin V-FITC and PI and analyzed by flow cytometry; and apoptosis pathway was studied by analysis of caspase-3, -8, and -9 activation, mitochondrial accumulation of Bax and Bak, and cytochrome c release. Results: SG remarkably enhances cancer cell death induced by epirubicin or paclitaxel in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells. Results of the mechanism study highlighted the cooperation between SG and epirubicin or paclitaxel in activating caspase-3 and -9 but not caspase-8. Moreover, SG significantly increased the mitochondrial accumulation of both Bax and Bak triggered by epirubicin or paclitaxel as well as the subsequent release of cytochrome c in the targeted cells. Conclusion: SG significantly potentiated the anticancer activities of epirubicin and paclitaxel in a synergistic manner. These effects were associated with the increased mitochondrial accumulation of both Bax and Bak that led to an enhanced cytochrome c release, caspase-9/-3 activation, and apoptosis. Treating cancer cells by combining epirubicin and paclitaxel with SG may prove to be a novel strategy for enhancing the efficacy of the two drug types.
Introduction
Cancer is one of the most fatal diseases that poses a threat to human health worldwide [1] . A deviant regulation of apoptosis is required for cancer initiation, development, and metastasis [2] . Recent anticancer treatment, including chemotherapy, immunotherapy, radiation, and cytokines, primarily induce apoptosis in targeted cancer cells [3] . Apoptosis, a programmed cell death, is initiated through two main pathways: the exogenous pathway, which is characterized by death receptor activation; and the endogenous pathway, which is characterized by mitochondrial destruction [4] . The tumor necrosis factor receptor superfamily triggers the membrane receptor aggregation and then recruits Fas associated death domain (FADD) and caspase-8 by binding of its specific ligand. Upon recruitment, caspase-8 becomes activated and initiates apoptosis through the direct cleavage of the downstream effector caspases, particularly caspase-3 and -7. In the mitochondrial pathway, apoptogenic factors, such as cytochrome c, second mitochondria-derived activator of caspases (Smac), or apoptosisinducing factor (AIF), are released into the cytosol from the mitochondria. Cytochrome c triggers the activation of caspase-9 by forming the cytochrome c/apoptotic protease-activating factor (Apaf-1)/caspase-9-containing apoptosome complex. Meanwhile, Smac promotes the activation of caspase by invaliding the inhibitory effects of the inhibitors of apoptosis (IAP) family [5e7] . Combination treatments prove to be advantageous in treating malignancies that still partially respond to a single treatment [8] . Drugs have long been combined to treat diseases and reduce suffering; this long-standing history of drug combinations is clearly depicted in traditional Chinese medicines [9] .
Panax ginseng has been long used for several thousand years in the Orient as a tonic, prophylactic, and restorative agent [10] . Sun ginseng (SG), a new type of ginseng that is processed by heating at specific pressures, contains approximately equal amounts of three major ginsenosides (RK1, Rg3, and Rg5). SG reportedly serves several functions, including radical scavenging and antitumorpromoting activities [11e13] . Ginsenoside Rg3, one of the most studied of the three major ginsenosides, is reported to inhibit the proliferation, migration, and invasion in many common cancers, such as liver, prostate, colorectal, and ovarian, and has been widely used in cancer treatment [14e17] . Rg3 can induce apoptosis and cell cycle arrest in different cancer cells via different pathways such as downregulating hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) [18e21]. Rk1 was investigated to inhibit telomerase activity and cell growth and induce apoptosis through activation of caspase-8 and -3 via ERK pathway, whereas another article demonstrated that Rk1 could induce G1 arrest and autophagy [22, 23] . Rg5 blocks the cell cycle at the Gl/S transition phase by increasing p21Cip/WAF1 and decreasing cyclin E and CDK2 [24] .
Epirubicin is a third-generation anthracycline that treats a broad spectrum of cancers, including cervical, breast, lung (especially small cell lung cancer), ovarian, stomach, colon, and bladder, and malignant lymphoma [25, 26] . Similar to widely used anticancer drugs, epirubicin exhibits some adverse effects on blood, the stomach, and the heart; these effects largely depend on the applied doses [27] . Paclitaxel is another important anticancer drug that is widely used as a chemotherapeutic agent for treating ovarian, breast, lung, colorectal, bladder, prostate, and gastric cancer, melanoma, and lymphoma [28e30]. Paclitaxel, which is an inhibitor of microtubule degradation, induces cell cycle arrest at the G2/M phase [31, 32] and ultimately apoptosis [33, 34] . This drug also has significant adverse effects, such as hypersensitivity, neutropenia syndrome, neurotoxicity, heart rhythm disorders, and intracellular toxicity [35e37] . Therefore, developing adjuvant agents to potentiate the anticancer activities of epirubicin and paclitaxel and to minimize their adverse effects is significant.
In the current study, SG significantly potentiated the anticancer activities of epirubicin and paclitaxel in a synergistic manner. These effects were associated with the increased mitochondrial accumulation of both Bax and Bak that led to an enhanced cytochrome c release, caspase-9/-3 activation, and apoptosis.
Materials and methods

Materials
SG was provided by Dr. Jeong Hill Park, College of Pharmacy, Seoul National University, Seoul, Korea. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), and dimethylsulfoxide (DMSO) were purchased from SigmaeAldrich (St. Louis, MO, USA). Epirubicin was acquired from Pfizer (Wuxi, China). Newborn calf serum and Dulbecco modified Eagle's medium (DMEM) were purchased from Gibco (Life Technologies, Grand Island, NY, USA). Caspase substrates Ac-DEVD-AFC, Ac-IETD-AFC, and Ac-LEHD-AFC were purchased from Calbiochem (La Jolla, CA, USA). The Mitochondria Isolation Kit was purchased from Pierce (Rockford, IL, USA). Annexin V-FITC Apoptosis Detection Kit was purchased from KeyGEN Biotech (Nanjing, China). Polyvinylidene difluoride (PVDF) membrane was purchased from Millipore (Billerica, MA, USA). Antibodies against cytochrome c, poly (adenosine diphosphateribose) polymerase (PARP), Bak, Bax, a-tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against caspase-8, -9, and cytochrome c oxidase II (Cox II) were purchased from Cell Signaling Technology (Beverly, MA, USA). Clarity Western ECL Substrate Kit was purchased from Bio-Rad (Hercules, CA, USA).
Cell culture
HeLa, SW111C, and SW480 cells were grown in DMEM supplemented with 10% (by volume) heat-inactivated newborn calf serum, 100 mg/mL of streptomycin 100 U/mL of penicillin, at 37 C in a humidified atmosphere with 5% CO 2 .
Analysis of SG methanol extract
The SG methanol extract was analyzed as a previous report described [38] . Briefly, SG was dissolved in MeOH (3 mg/mL), and filtered with 0.45mm Millipore filter, and the solution was analyzed with a Waters 2695 liquid chromatograph (Waters Corporation, Milford, MA, USA) fitted with Knauer C-18, reverse-phase column (Knauer, Berlin, Germany; 5mm,4250 mm Â 3 mm) utilizing the solvent gradient system. The mobile phase consisted of acetonitrile water (Solvent A) and water (Solvent B) and the flow rate was 0.6 mL/min. The detector was a Waters 2996 PDA Detector (Waters Corporation). The gradient elution was used as follows: 0e20 min, 20% A; 20e31 min, linear gradient from 20e32% A; 31e40 min, linear gradient from 32e43% A; 40e70 min, linear gradient from 43e100% A; and 70 min, 100% A.
MTT assay
Exponentially growing cells were seeded into a 96-well plate at 0.8 Â 10 4 cells/well in triplicate. After incubation for 20 h, cells were treated with increasing concentrations of SG, epirubicin, or paclitaxel for 48 h. At 44 h posttreatment, 20 mL of MTT (5 mg/mL) was added to each well and incubated for 4 h. Then 150 mL of DMSO was added to every well to solubilize the formazan crystals formed by viable cells, and the color intensity was measured at 550 nm with an enzyme-linked immunosorbent assay plate reader (TECAN, Männedorf, Switzerland).
Apoptosis assay
HeLa cells were cultured for 20 h and then treated with 80 mg/ mL SG with 0.5 mg/mL epirubicin or 10nM paclitaxel alone or combined for 24 h. HeLa cells were harvested, washed with icecold phosphate buffered saline (PBS), and stained with annexin V/PI reagent as described previously [3] . The percentage of annexin V (þ) cells was determined by flow cytometry (Becton Dickinson FACS Calibur Cytometer, San Jose, CA, USA). The percentage of annexin V (þ) cells indicates the frequency of total apoptotic cells.
Cell-free caspase activity assay
As described [39] , HeLa were treated and harvested. 50 mg whole-cell lysates were incubated with 200nM Ac-LEHD-AFC (for caspase-9), Ac-IETD-AFC (for caspase-8), and Ac-DEVD-AFC (for caspase-3) in a reaction buffer containing 20mM
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4,10mM dithiothreitol (DTT), 10% sucrose, 100mM NaCl, and 0.1% 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS) at 37 C for 1 h. The reaction was monitored by fluorescence excitation at 405 nm and emission at 505 nm.
Preparation of mitochondrial and cytosolic protein extracts
HeLa cells were treated and harvested. Mitochondria and cytosolic protein extracts were prepared using a Mitochondria Isolation Kit (Pierce) according to the manufacturer's instructions. Isolated mitochondria were solubilized in a lysis buffer containing 20mM TriseHCl (pH 7.5), 1% NP-40, 150mM NaCl, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2mM MgCl 2 , 1mM ethylene glycol tetraacetic acid (EGTA), 50mM b-glycerol phosphate, 25mM NaF, 1mM DTT, 1mM Na 3 VO 4 with 2 mg/mL leupeptin, 2 mg/mL pepstatin A, 2 mg/mL antipain, and 1mM phenylmethylsulfonyl fluoride (PMSF). The mitochondrial proteins were then subjected to immunoblotting analysis using antibodies against Bax and Bak. The cytosolic proteins were subjected to immunoblotting analysis using antibody against cytochrome c.
Immunoblotting analysis
The treated cells were washed with ice-cold PBS and solubilized in a lysis buffer containing 20mM Tris with a pH of 7.5, 2mM MgCl 2 , 1mM DTT, 0.5% Triton X-100, 1mM EGTA, 25mM NaF, 1mM Na 3 VO 4 , 50mM Ò-glycerol phosphate, 2 mg/mL leupeptin, 2 mg/ mL pepstatin A, 2 mg/mL antipain, and 1mM PMSF. After incubating on ice for 1 h, the insoluble materials were removed by centrifugation at 14,000 Â g for 15 min. 50 mg of protein from each sample was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE), followed by electrotransfer onto a PVDF membrane (Millipore). The membrane was blocked with 5% nonfat milk in PBS with 0.1% Tween 20 and probed with the antibodies. The blots were washed and incubated with a horseradish peroxidasecoupled antimouse immunoglobulin G (IgG) or an antirabbit IgG antibody (Pierce) followed by detection with an electrogenerated chemiluminescence (ECL) revelation system (Bio-Rad).
Statistical analysis
All values are performed in triplicate and expressed as mean AE standard deviation with Microsoft Office 2013 and imaged with Sigmaplot 10 (Systat Software Inc, San Jose, CA, USA). A Student t test was used for quantitative analysis, and the significant difference is shown as * p < 0.05, **p < 0.01, and ***p < 0.001.
Results and Discussion
Analysis of SG extract
To determine the types of ginsenoside in SG, we analyzed MeOH extract of SG by an analytical high-performance liquid chromatography. As shown in Fig. 1 , the amount of four main ginsenosides in the total ginsenosides were 20(S)-Rg3 (11.33%), 20(R)-Rg3 (6.88%), Rk1 (16.72%), and Rg5 (11.97%).
Cytotoxic effect of SG on cancer cells
As shown in Fig. 1 , the amount of ginsenoside Rg3, Rg5, and RK1 reached 50% of total ginsenosides in SG. A number of studies showed that (20S) ginsenoside Rg3, Rg5, and RK1 inhibit cell viability in various human cancer cells. We then examined whether SG features cytotoxic activity in human cancer cells in human cervical adenocarcinoma HeLa cells, human colon cancer SW111C cells, and SW480 cells through an MTT assay. Fig. 2 illustrates that SG exhibited a moderate cytotoxicity against the HeLa, SW111C, and SW480 cells with IC50 values of 94 mg/mL, 78 mg/mL, and 224 mg/mL, respectively.
SG enhances the efficacy of anticancer drugs epirubicin and paclitaxel
To examine whether SG enhances the efficacy of clinical anticancer drugs, we determined the half maximal inhibitory concentration (IC50) values of epirubicin and paclitaxel, either alone or with a subtoxic concentration of SG, in the three cancer cell lines (HeLa, SW111C, and SW480). Fig. 3 and Table 1 depict that the IC50 values markedly decreased with the addition of SG to epirubicin and paclitaxel. The IC50 value of epirubicin in the HeLa cells was 1.05 mg/mL, which decreased to 0.15 mg/mL with the addition of 80 mg/mL SG. This result indicates that a subtoxic concentration of SG significantly increases the cytotoxic efficacy of epirubicin. SG exhibited similar potentiating activities on paclitaxel in all three cancer cell lines.
SG helps induce strong apoptotic cell death in HeLa cells
To examine whether the role of SG in the cytotoxic effect of epirubicin and paclitaxel was caused by the enhanced apoptosis, we assessed the resulting apoptosis in the HeLa cells after separate treatments with epirubicin and paclitaxel alone and after the treatment with the combination of SG and the two drugs. The stage of apoptosis was determined through annexin-V analysis. As shown A Student t test was used for quantitative analysis, and the significant difference is shown as * p < 0.05, **p < 0.01, and ***p < 0.001.
in Fig. 4A and C, the percentage of apoptotic cells was considerably higher in the cotreated cells than in the epirubicin-and paclitaxeltreated cells. To determine the activation of caspase in the cells, we detected the PARP cleavage through immunoblotting analysis. Fig. 4B and D show that PARP was cleaved to yield an 85-kD fragment in the drug-treated cells and that the amount of the cleaved 85-kD fragment was more significant in the co-treated cells than in the epirubicin-and paclitaxel-treated cells. On the basis of these results, we suggest that SG enhances the anticancer activities of epirubicin and paclitaxel through caspase-associated apoptosis.
SG enhances apoptosis via the mitochondrial pathway
To elucidate the initiation event of apoptosis, we inspected the activation kinetics of the two initiator caspases, namely, caspase-8 and -9, and the effector caspases, caspase-3/-7. As shown in Fig. 5 , the activities of caspase-9 and -3/-7 greatly increased in the cotreated cells than in the epirubicin-and paclitaxel-treated cells. By contrast, the activity of caspase-8 did not show any change in all cells. We then determined the cleavage of caspase-9 and -8. Specifically, we examined the proteolytic activation of these caspases through immunoblotting analysis. Apparent cleavage was observed in caspase-9 but not in caspase-8. The amounts of the active form of the cleaved caspase-9 were higher in the cotreated cells than in the epirubicin-and paclitaxel-treated cells. The data suggest that epirubicin and paclitaxel-induced apoptosis might be potentiated by SG via the intrinsic apoptosis pathway in HeLa cells.
Apoptosis of SG-enhanced HeLa cells mediated through cytochrome C release
The release of mitochondrial cytochrome c is the crucial event in caspase-9 activation [40] . The family members of the Bcl-2 family, namely, Bax and Bak, serve as an essential gateway for the release of cytochrome c [5, 41] . Fig. 6 shows that cytochrome c appeared in cytosol after the cell was treated with the two drugs; the levels of this protein in the cytosol were much higher in the SG and epirubicin or paclitaxel-treated HeLa cells than in the epirubicin-and paclitaxel-treated cells. Similarly, the levels of Bax and Bak in the mitochondria were markedly increased in the epirubicin-and paclitaxel-treated cells, but this increase was more significant in the cotreated groups (Fig. 7) . Moreover, the increase of Bax and Bak in the mitochondria upon drug treatment conformed well to the release of the enhanced cytochrome c in the apoptotic cells. However, no evident changes were observed in Bax or Bak in the wholecell lysates. These results imply that the increased regulation of the released cytochrome c that was observed in the co-treated HeLa cells resulted from the enhanced translocation of Bax and Bak proteins.
The induction of apoptosis in cancer cells is a staple killing mechanism for most antitumor therapies [2] . The cotreatment of anticancer reagents has been shown to be advantageous in malignancies that still partially respond to epirubicin or paclitaxel treatment because they may help amplify weak death signals. In this study, SG markedly potentiated epirubicin-or paclitaxelinduced cancer cell death possibly because of the increase in the analyzed by immunoblotting using specific antibodies against caspase-8, caspase-9, and a-tubulin. release of cytochrome c and the activation of caspases-9 and -3. Thus, cotreating cancer cells with SG and clinical drugs could be a novel strategy for enhancing the efficacy of current chemotherapies. The development of SG as a new adjuvant drug for cancer therapy also shows great potential.
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